The senator called for unity among progressives because "we cannot have four more years of Donald Trump in the White House."

With the 2024 presidential race beginning to unfold, Sen. Bernie Sanders of Vermont said he believes that President Joe Biden will again earn the Democratic nomination — and the president likely win reelection if he runs on a strong progressive campaign.

“I think at this moment … we have got to bring the progressive community together to say, you know what, we’re going to fight for a progressive agenda but we cannot have four more years of Donald Trump in the White House,” Sanders said Sunday on “Face the Nation.”

…

Sanders endorsed Mr. Biden in April. Sanders referenced several of those issues in underscoring what he believes is the importance of building “a strong progressive agenda” to win the presidency in 2024.

  • Boddhisatva@lemmy.world
    11·
    1 year ago

    If Biden were to make any such change to Marijuana scheduling by executive order, the next president would just undo it the same way. Worse still, the GOP would use such a move as a talking point that Biden is soft on crime and trying to get their kids on drugs, which the GOP base would eat up.

    In fact, though, the Biden administration actually is making progress on this front. Some time ago, they requested that U.S. Department of Health and Human Services study whether or not Marijuana should be rescheduled. Just a few days ago, HHS sent their recommendation to the DEA to reschedule marijuana from a Schedule I drug to a Schedule III drug. The DEA has sole authority on drug scheduling.

    “While HHS’s scientific and medical evaluation is binding on DEA, the scheduling recommendation is not,” the HHS spokesperson said. “DEA has the final authority to schedule a drug under the CSA (or transfer a controlled substance between schedules or remove such a drug from scheduling altogether) after considering the relevant statutory and regulatory criteria and HHS’ scientific and medical evaluation. DEA goes through a rulemaking process to schedule, reschedule or deschedule the drug, which includes a period for public comment before DEA finalizes the scheduling action with a final rulemaking.”